Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

FOFO vs ASTH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ASTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

ASTH Overall Winner 6-Pillar Tally: FOFO 0 – 6 ASTH Matrix Metrics: FOFO 0 – 10 ASTH

As of Nov 20, 2026, Astrana Health Inc. (ASTH) is the stronger overall head-to-head candidate over Hang Feng Technology Innovation Co., Ltd. (FOFO) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FOFO carries a Unified Composite Score of 43.0/100 (HOLD) at $1.50 (N/M Forward P/E, -823.6% operating margin), whereas ASTH carries 48.8/100 (HOLD) at $28.90 (8.3x Forward P/E, 2.6% operating margin).

  • Technical & Structure Timing Caution: FOFO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.2); meanwhile ASTH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FOFO vs ASTH
FOFO NASDAQ
Hang Feng Technology Innovation Co., Ltd. Ordinary Shares
Services-Management Consulting Services
$1.50
-7.41% 1D
Market Cap $12.8M
TTM Revenue $1.4M
Forward P/E N/M
Beta / 30D Vol 0.45β · 65% Vol
Unified Composite Score
43.0 / 100 HOLD
Tech 33.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.8%), weak momentum, RSI 29
RSI-14: 29.2 · SMA20: $1.75 · SMA50: $1.91
ASTH NASDAQ Head-to-Head Winner
Astrana Health Inc. Common Stock
Services-Management Consulting Services
$28.90
+0.77% 1D
Market Cap $1.4B
TTM Revenue $3.91B
Forward P/E 8.3x
Beta / 30D Vol 0.40β · 60% Vol
Unified Composite Score
48.8 / 100 HOLD
Tech 53.0 Fund 55.0 Flow 55.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 30
RSI-14: 30.1 · SMA20: $34.27 · SMA50: $35.64

6-Pillar Scorecard Institutional Category Breakdown (FOFO 0 – 6 ASTH)

Columns: Metric · FOFO · ASTH
1. Valuation Multiples ASTH
Forward P/E N/M 8.3x
Trailing P/E N/M 26.6x
PEG Ratio N/M N/M
EV / Revenue 9.4x 0.5x
2. Growth & Scale ASTH
Revenue Growth (YoY) -72.7% +7.1%
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $1.4M $3.91B
Market Cap $12.8M $1.4B
3. Profitability & Quality ASTH
Gross Margin 7.0% 11.0%
Operating Margin -823.6% 2.6%
Net Profit Margin 0.0% 1.4%
Return on Equity (ROE) -169.2% 9.8%
4. Balance Sheet & Cash Flow ASTH
Cash Generation (TTM) -$11M EBITDA $99M
Cash Flow Margin N/A 2.5%
Net Cash / Leverage $1.02 Book/Sh · -169.2% ROE $581M Net Debt (1.14x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ASTH
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 52.0% (8th %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ASTH
OpEx & R&D Intensity N/A 8.4% of Rev ($329M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Consulting Services Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FOFO (0) vs ASTH (10)
Institutional Metric FOFO ASTH Criterion Row Edge
Market Capitalization
Scale
$12.8M $1.4B Larger Scale ASTH
Trailing P/E Ratio
Valuation
N/M 26.6x Lower Multiple ASTH
Forward P/E Ratio
Valuation
N/M 8.3x Lower Multiple ASTH
Revenue Growth (YoY)
Growth
-72.7% +7.1% Higher Growth ASTH
Operating Margin (TTM)
Profitability
-823.6% 2.6% Higher Margin ASTH
Net Profit Margin
Profitability
0.0% 1.4% Higher Margin ASTH
Return on Equity (ROE)
Capital Efficiency
-169.2% 9.8% Higher ROE ASTH
52-Week Range Position
Momentum
0% ($2–$15) 32% ($18–$52) Stronger Trend ASTH
Beta / 30D Volatility
Risk Regime
0.45β · 65% Vol 0.40β · 60% Vol Lower Realized Risk ASTH
Unified Institutional Score
Composite Signal
43.0 / 100 (HOLD) 48.8 / 100 (HOLD) Higher Composite ASTH
Trailing 12M Revenue (USD)
Operating Scale
$1.4M $3.91B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
7.0% 11.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.4x EV/Rev N/M PEG · 0.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($1.02 Book/Sh · -169.2% ROE) $99M ($581M Net Debt (1.14x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FOFO +0.11 pp
FOFO: -23.86% · ASTH: -23.97%
3M Horizon ASTH +14.61 pp
FOFO: -38.78% · ASTH: -24.17%
6M Horizon ASTH +1.35 pp
FOFO: -25.0% · ASTH: -23.65%
1Y Horizon ASTH +117.07 pp
FOFO: -85.89% · ASTH: +31.18%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FOFO vs ASTH. Trailing 12-month operating profitability (FOFO -823.6% vs ASTH 2.6%) and valuation multiples (FOFO N/M vs ASTH 8.3x Forward P/E) are benchmarked directly in Pillar 4 below.

FOFO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.4M
Gross Margin7.0%
Op. Margin-823.6%
ROE / Fwd P/E-169.2% · N/M
ASTH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.91B
Gross Margin11.0%
Op. Margin2.6%
ROE / Fwd P/E9.8% · 8.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FOFO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FOFO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ASTH BREAKDOWN
100d in phase · OBV NEUTRAL
Current IV 52.0%
IV Percentile 8th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ASTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FOFO Moat Profile Cyclical / Execution-Driven Positioning
Consulting Services Operator
Competes within the Consulting Services value chain with $12.8M market capitalization and -823.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ASTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $1.4B market capitalization and 2.6% operating margin.
OpEx & R&D Reinvestment 8.4% of Rev ($329M)
90D Engineering Disclosures 0 Published

Investor FAQ FOFO vs ASTH Key Questions & Quantitative Answers

As of Nov 20, 2026, Astrana Health Inc. (ASTH) is the stronger overall head-to-head candidate over Hang Feng Technology Innovation Co., Ltd. (FOFO) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FOFO carries a Unified Composite Score of 43.0/100 (HOLD) at $1.50 (N/M Forward P/E, -823.6% operating margin), whereas ASTH carries 48.8/100 (HOLD) at $28.90 (8.3x Forward P/E, 2.6% operating margin). Technical & Structure Timing Caution: FOFO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.2); meanwhile ASTH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ASTH leads the Growth & Scale pillar: FOFO posts -72.7% YoY revenue growth and +0.0% YoY earnings growth on $1.4M TTM revenue (7.0% gross margin, -823.6% operating margin), compared with ASTH at +7.1% YoY revenue growth and N/A YoY earnings growth on $3.91B TTM revenue (11.0% gross margin, 2.6% operating margin). On trailing 12-month operating scale, FOFO generates $1.4M in USD-normalized revenue versus $3.91B for ASTH. In operating R&D and SG&A reinvestment, FOFO deploys N/A (0 90-day corporate R&D disclosures) versus 8.4% of Rev ($329M) (0 disclosures) for ASTH.

ASTH screens cheaper on headline valuation multiples. FOFO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.4x EV/Revenue (unreported EBITDA margin), whereas ASTH trades at 8.3x Forward P/E, 26.6x Trailing P/E, N/M PEG, and 0.5x EV/Revenue (2.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FOFO (-169.2% ROE) versus ASTH (9.8% ROE) capital efficiency.

In options market volatility and institutional positioning, FOFO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 65% Vol realized risk). By comparison, ASTH carries 52.0% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.40β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.